Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis

Cancer Research

Volumn 61, Issue 4, 2001, Pages 1645-1651

  Lacour, Sandrine ^a   Hammann, Arlette ^a   Wotawa, Anne ^a   Corcos, Laurent ^a   Solary, Eric ^a   Dimanche Boitrel, Marie Thérèse ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 8; CISPLATIN; DOXORUBICIN; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN BCL 2; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL DEATH; CELL MEMBRANE PERMEABILITY; CELL SURFACE; COLON CARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CASPASE 3; CASPASE 8; CASPASE 9; CASPASES; CELL MEMBRANE; CISPLATIN; COLONIC NEOPLASMS; DOXORUBICIN; DRUG SYNERGISM; ENZYME ACTIVATION; HUMANS; MEMBRANE GLYCOPROTEINS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR; SOLUBILITY; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035866369     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Identification and characterization of a new member of the TNF family that induces apoptosis
2. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor family
3. TRAIL: A molecule with multiple receptors and control mechanisms
4. Apoptosis by death factor
5. Safety and antitumor activity of recombinant soluble Apo2 ligand
6. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo
7. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosisinducing ligand
8. Human brain-cell death induced by tumor-necrosis-factor-related apoptosis-inducing ligand
9. The receptor for the cytotoxic ligand TRA1L
10. An antagonistic decoy receptor and a death domain-containing receptor for TRAIL
11. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors
12. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-ΚB
13. TRAIL-R2: A novel apoptosis-mediating receptor for TRAIL
14. Cloning and characterization of TRAIL-R3. A novel member of the emerging TRAIL receptor family
15. The novel receptor TRAIL-R4 induces NF-ΚB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain
16. A novel receptor for Apo2L/TRAIL contains a truncated death domain
17. TRUNDD, a new member of TRAIL receptor family that antagonizes TRAIL signaling
18. Death receptor 5, a new member of TNFR family and DR4 induce FADD-dependent apoptosis and activate the NF-ΚB pathway
19. Mechanisms of resistance of normal cells to TRAIL-induced apoptosis vary between different cell types
20. TRAIL receptor-2 signals apoptosis through FADD and caspase-8
21. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2
22. FADD is required for DR4- and DR5-mediated apoptosis
23. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1 and TNF receptor-induced cell death
24. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex
25. FLICE is activated by association with the CD95 deathinducing signaling complex (DISC)
26. Molecular ordering of apoptotic mammalian CED-3/1CE-like proteases
27. TRAIL causes cleavage of Bid by caspase-8 and loss of mitochondrial membrane potential resulting in apoptosis in BJAB cells
28. Inhibition of death receptor signals by cellular FLIP
29. Molecular determinants of response to TRAIL in killing of normal and cancer cells
30. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene
31. p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor
32. Induction of the TRAIL receptor KILLER/DR5 in p53-dependent apoptosis but not growth arrest
33. Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL
34. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines
35. Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: The trail to non-toxic cancer therapeutics
36. Sensitization of cancer cells treated with cytotoxic drugs to Fas-mediated cytotoxicity
37. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma
38. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL
39. Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells
40. Synergistic cytotoxicity and apoptosis by Apo-2 ligand and Adriamycin against bladder cancer cells
41. Fas-ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs
42. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells
43. Cell-cycle-dependent regulation of FLIP levels and susceptibility to Fas-mediated apoptosis
44. The inhibitor of death receptor signalling. FLICE-inhibitory protein defines a new class of tumor progression factors
45. Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein
46. 1-FLICE, a novel inhibitor of tumor necrosis factor receptor-1 and CD-95-induced apoptosis
47. The role of c-FLIP in modulation of CD95-induced apoptosis
48. Bid, a Bcl-2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors
49. Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis
50. Locoregional Apo2L/FRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity